fregime

What actually happened to the stocks you care about: every claim cited, corroboration counted, never opinions.

SAIPARENT · NSE

Sai Parenterals

₹530.90

+0.57%

Close (EOD), as of 26 Aug 2026 · source

Not in active coverage. Cited reporting has mentioned Sai Parenterals, the record of those mentions is below. Your interest is logged; coverage expands by demand.

Mentions in cited reporting

Sai Parenterals' Australian OTC supply book reached AU$232 million (about ₹1,506 crore) after its subsidiary Noumed Pharmaceuticals renewed a three-year supply agreement worth AU$30 million with a pharmacy chain.

cnbctv18.comsingle-source report25 Aug 2026

Every claim carries its citation

This page lists where cited reporting has mentioned Sai Parenterals. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.